| 1 |
34183756 | Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therapy. | 2022 Apr |
1 |
| 2 |
33476691 | Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy. | 2021 Mar |
1 |
| 3 |
34326139 | Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4. | 2021 Sep |
2 |
| 4 |
31748224 | Piperine Is a Mechanism-Based Inactivator of CYP3A. | 2020 Feb |
2 |
| 5 |
31833760 | "Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4": Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping. | 2020 Feb 17 |
1 |
| 6 |
31414593 | Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4. | 2019 Sep 16 |
1 |
| 7 |
29027845 | The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. | 2018 Oct |
1 |
| 8 |
27935260 | In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. | 2017 Aug |
1 |
| 9 |
28618157 | Liver microsomal lipid enhances the activity and redox coupling of colocalized cytochrome P450 reductase-cytochrome P450 3A4 in nanodiscs. | 2017 Jul |
3 |
| 10 |
28786954 | Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats. | 2017 Aug 8 |
1 |
| 11 |
26490246 | Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone. | 2016 Jan |
1 |
| 12 |
25322914 | Time-dependent inhibition of CYP3A4 by gallic acid in human liver microsomes and recombinant systems. | 2015 Mar |
1 |
| 13 |
26038696 | Human hepatic metabolism of the anti-osteoporosis drug eldecalcitol involves sterol C4-methyl oxidase. | 2015 Mar |
1 |
| 14 |
26066995 | Anion-Dependent Stimulation of CYP3A4 Monooxygenase. | 2015 Jul 7 |
1 |
| 15 |
26293521 | Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin. | 2015 Sep |
2 |
| 16 |
24430948 | Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. | 2014 Jun |
2 |
| 17 |
25273356 | Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds. | 2014 Dec |
1 |
| 18 |
25521355 | POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. | 2014 Dec |
1 |
| 19 |
23257392 | Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. | 2013 |
1 |
| 20 |
23500771 | Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. | 2013 Jun |
1 |
| 21 |
23929629 | Time-dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor. | 2013 Nov |
1 |
| 22 |
22014153 | Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. | 2012 Apr |
1 |
| 23 |
22313038 | Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. | 2012 Jul |
1 |
| 24 |
22382318 | Mechanism-based inhibition of recombinant human cytochrome P450 3A4 by tomato juice extract. | 2012 |
2 |
| 25 |
22851614 | Oxidative ipso substitution of 2,4-difluoro-benzylphthalazines: identification of a rare stable quinone methide and subsequent GSH conjugate. | 2012 Nov |
1 |
| 26 |
21402692 | CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). | 2011 May 20 |
1 |
| 27 |
21447734 | Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction. | 2011 Jul |
2 |
| 28 |
21673127 | A novel biotransformation of alkyl aminopyrrolidine to aminopiperidine ring by human CYP3A. | 2011 Sep |
1 |
| 29 |
21766881 | Cytochromes P450 catalyze the reduction of α,β-unsaturated aldehydes. | 2011 Aug 15 |
1 |
| 30 |
20100816 | Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction. | 2010 May |
1 |
| 31 |
20624855 | Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. | 2010 Oct |
1 |
| 32 |
20673718 | Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study. | 2010 Sep 1 |
1 |
| 33 |
20849814 | Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. | 2010 Oct 8 |
2 |
| 34 |
20879989 | Kinetics of electron transfer between NADPH-cytochrome P450 reductase and cytochrome P450 3A4. | 2010 Dec 15 |
1 |
| 35 |
18653741 | CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance. | 2008 Oct |
1 |
| 36 |
18799803 | 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. | 2008 Dec |
1 |
| 37 |
18803184 | Kinetic study of cytochrome P450 by capillary electrophoretically mediated microanalysis. | 2008 Sep |
1 |
| 38 |
17213193 | Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. | 2007 Mar 9 |
2 |
| 39 |
18043468 | Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. | 2007 Dec |
1 |
| 40 |
16611021 | Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. | 2006 Apr |
2 |
| 41 |
16862439 | Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego. | 2006 Oct |
1 |
| 42 |
15608130 | Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. | 2005 Mar |
2 |
| 43 |
15735612 | Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. | 2005 Mar |
1 |
| 44 |
15744076 | Mechanism-based inhibition of CYP3A4 by constituents of Zingiber aromaticum. | 2005 Mar |
1 |
| 45 |
15762770 | Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. | 2005 |
4 |
| 46 |
15763633 | Inhibition of human cytochrome P450 3A4 activity by zinc(II) ion. | 2005 Apr 28 |
1 |
| 47 |
15770073 | Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. | 2005 Feb |
6 |
| 48 |
15801939 | Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. | 2005 Apr |
1 |
| 49 |
15922009 | Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. | 2005 Jun 15 |
1 |
| 50 |
18360537 | Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. | 2005 Mar |
1 |